Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7M | 6M | 6M | 6M | 5M |
| Gross Profit | 3M | 3M | 2M | 2M | 2M |
| Operating Income | 1M | 853K | 679K | 666K | 516K |
| EBITDA | 1M | 1M | 716K | 700K | 1M |
| Net Income | 1M | 884K | 768K | 493K | 995K |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$0.83
-2.35% today
1Y Change
-6.25%
Window
Jun 23, 2025 → Jun 12, 2026
Coverage: 245 bars · Jun 23, 2025 → Jun 12, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Pacific Health Care Organization, Inc. (PFHO) is a Healthcare stock with a market cap of $10.00M and listed on OTC. The stock last traded around $0.83 and down 6.3% across the available one-year price window (Jun 23, 2025 → Jun 12, 2026). Baseline metrics include revenue growth of +10.7%, EPS growth of +59.4%, a dividend yield of 0.0%. What stands out right now is revenue +10.7%, EPS +59.4%, free cash flow +70.8% with operating margin 13.4% and ROIC -148.4%. Valuation is more restrained than many high-expectation growth names at P/E 10.9 and price/sales 2.2. Stock Foundry combines PFHO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
PFHO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
PFHO Max Drawdown
-35.25%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for PFHO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$5.4M
-6.0% YoY
FY Net Income
$995.0K
+101.9% YoY
Free Cash Flow
$368.0K
-45.3% YoY
Revenue Growth
+10.7%
EPS Growth
+59.4%
Gross Margin
50.0%
Net Margin
20.2%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 7M | 6M | 6M | 6M | 5M |
| Gross Profit | 3M | 3M | 2M | 2M | 2M |
| Operating Income | 1M | 853K | 679K | 666K | 516K |
| EBITDA | 1M | 1M | 716K | 700K | 1M |
| Net Income | 1M | 884K | 768K | 493K | 995K |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 2M | 2M | 3M | 2M | 10M |
| Total Assets | 13M | 12M | 12M | 12M | 11M |
| Total Liabilities | 402K | 746K | 1M | 735K | 508K |
| Shareholder Equity | 13M | 12M | 11M | 11M | 11M |
| Total Debt | 0 | 35K | 56K | 50K | 70K |
| Net Debt | -2M | -2M | -3M | -2M | -10M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
386K
-45.7% YoY
Capital Expenditures
18K
+52.7% YoY
Free Cash Flow
368K
-45.3% YoY
Key ratios
Gross Margin
50.0%
Operating Margin
13.4%
Net Margin
20.2%
ROE
10.0%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.